JENA, Germany & MANCHESTER, England--(BUSINESS WIRE)--SIRS-Lab GmbH and DxS Ltd today announced that they entered into an EU-wide in-licensing agreement for the Scorpions Technology including an option for worldwide IVD utilization. With the selection of the PCR platform technology, SIRS-Lab completes the technical design of its sepsis prediction and monitoring test SIQNATURE. The first-in-class test is now accessible for selected scientific experts and will be fully available in 2009.
